Risk prediction for clonal cytopenia: multicenter real-world evidenceZhuoer Xie, Aref Al‐Kali, Rami S. Komrokji et al.|Blood|2024Cited by 51
The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal CytopeniasZhuoer Xie, Aref Al‐Kali, Alexandra N. Smith et al.|Blood|2022Cited by 6
Characteristics and Clinical Outcome of Patients with Clonal Cytopenias of Undetermined Significance: A Large Retrospective Multi-Center International StudyZhuoer Xie, Aref Al‐Kali, Rami S. Komrokji et al.|Blood|2021Cited by 6
Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate DatabaseBenjamin Rolles, Valeria Santini, Jan Philipp Bewersdorf et al.|Blood|2024Cited by 5
Ivosidenib leads to durable responses in IDH1 mutated clonal cytopenias of undetermined significance: A phase II decentralized clinical trialKelly L. Bolton, Eytan M. Stein, Yazan F. Madanat et al.|Blood|2025Cited by 2